Charles Schwab
RVMD icon

Charles Schwab’s Revolution Medicines RVMD Stock Holding History

Charles Schwab’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$359M Buy
1,917,025
+181,549
+10% +$26.5M 0.05% 308
2026
Q1 		$169M Buy
1,735,476
+51,747
+3% +$5.23M 0.03% 484
2025
Q4 		$134M Buy
1,683,729
+48,334
+3% +$3.17M 0.02% 575
2025
Q3 		$76.4M Buy
1,635,395
+34,702
+2% +$1.36M 0.01% 867
2025
Q2 		$58.9M Sell
1,600,693
-329,775
-17% -$12.7M 0.01% 999
2025
Q1 		$68.3M Sell
1,930,468
-646
-0% -$26.2K 0.01% 858
2024
Q4 		$84.5M Buy
1,931,114
+167,997
+10% +$8.48M 0.02% 757
2024
Q3 		$80M Buy
1,763,117
+653,433
+59% +$28.5M 0.02% 796
2024
Q2 		$43.1M Buy
1,109,684
+57,421
+5% +$2.15M 0.01% 1187
2024
Q1 		$33.9M Buy
1,052,263
+9,296
+0.9% +$276K 0.01% 1277
2023
Q4 		$29.9M Buy
1,042,967
+276,298
+36% +$6.64M 0.01% 1333
2023
Q3 		$21.2M Buy
766,669
+55,558
+8% +$1.65M 0.01% 1473
2023
Q2 		$19M Buy
711,111
+53,884
+8% +$1.32M 0.01% 1540
2023
Q1 		$14.2M Buy
657,227
+94,140
+17% +$2.32M ﹤0.01% 1698
2022
Q4 		$13.4M Buy
563,087
+22,715
+4% +$483K ﹤0.01% 1685
2022
Q3 		$10.7M Buy
540,372
+95,969
+22% +$2.11M ﹤0.01% 1794
2022
Q2 		$8.66M Buy
444,403
+191
+0% +$3.72K ﹤0.01% 1916
2022
Q1 		$11.3M Buy
444,212
+13,134
+3% +$286K ﹤0.01% 1885
2021
Q4 		$10.9M Buy
431,078
+5,238
+1% +$148K ﹤0.01% 1959
2021
Q3 		$11.7M Buy
425,840
+70,898
+20% +$2.06M ﹤0.01% 1912
2021
Q2 		$11.3M Buy
354,942
+40,136
+13% +$1.4M ﹤0.01% 1932
2021
Q1 		$14.4M Buy
314,806
+47,735
+18% +$2.14M 0.01% 1749
2020
Q4 		$10.6M Buy
267,071
+2,532
+1% +$100K ﹤0.01% 1837
2020
Q3 		$9.21M Buy
264,539
+167,008
+171% +$4.63M ﹤0.01% 1753
2020
Q2 		$3.08M Buy
97,531
+67,650
+226% +$2.13M ﹤0.01% 2267
2020
Q1 		$655K Buy
+29,881
New +$827K ﹤0.01% 2617

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Charles Schwab's RVMD Position: Q2 2026 in Review

Charles Schwab increased its Revolution Medicines (RVMD) stake by 10% in Q2 2026, buying an estimated $26.5M and bringing the position to 1,917,025 shares worth $359M. The position accounts for 0.05% of the portfolio, ranked #308.

Charles Schwab first reported a position in RVMD in Q1 2020 and has held it in 26 quarters since. 689 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Charles Schwab held 1,917,025 shares of Revolution Medicines worth $359M as of Q2 2026.
  • Charles Schwab bought 181,549 Revolution Medicines shares in Q2 2026, an estimated $26.5M.
  • Revolution Medicines made up 0.05% of Charles Schwab's portfolio in Q2 2026, its #308 holding.
  • Charles Schwab first reported a position in Revolution Medicines in Q1 2020 and has held it in 26 quarters since.
  • 689 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.